skip to content


Skyepharma inks licence agreement

07 June 2016 15:00

Skyepharma has signed an exclusive feasibility, development and licence agreement with Lucideon Limited, part of Lucideon Group Ltd, the international materials development and commercialisation organisation, giving Skyepharma access to Lucideon's iCRT-deter abuse deterrent controlled release technology.

Skyepharma initially intends to use the technology to develop an abuse deterrent formulation of a major opioid for the U.S. market which according to GBI Research is set to grow from $11 billion in 2014 to $17.7 billion by 20211. The companies will collaborate over the coming months to assess the feasibility of using the technology in this novel way. Skyepharma will fund this development work, in line with current R&D spend plans. Lucideon will provide specialist expertise with its technology and Skyepharma's oral business will formulate the product and complete an abuse deterrence challenge study. If the feasibility stage is successful, Skyepharma's oral business plans to develop the product as a generic for the U.S. market.

At 3:00pm:

(LON:SKP) SkyePharma PLC share price was +0.13p at 448.88p

Story provided by

Related Company: SKP

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?


Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.